AtriCure (ATRC) Tops Q3 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Nasdaq ticks up as tech stocks steady; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
AtriCure Inc. (ATRC) PT Raised to $92 at Needham & Company
November 4, 2021 6:44 AM EDTNeedham & Company analyst Mike Matson raised the price target on AtriCure Inc. (NASDAQ: ATRC) to $92.00 (from $90.00) while maintaining a Buy rating.
The analyst commented, "ATRC's 3Q21 revenue, EBITDA, and EPS all beat consensus. While it has only been 6 months since EPi-Sense's FDA... More



